News

Updated Patient Resources for Ovarian Cancer from the Natio...

Updated Patient Resources for Ovarian Cancer from the National Comprehensive Cancer Network

July 31, 2017

(July 31, 2017) The National Comprehensive Cancer Network (NCCN), has updated and published guidelines for patients with ovarian cancer. There are two parts to the resource guide: The Guidelines for Patients and Quick Guides. The NCCN Guidelines for Patients is an in depth look at topics such as testing, stages of cancer, and treatments. There … Continued

OCRFA Funded Project Has Breakthrough on Therapeutic Approa...

OCRFA Funded Project Has Breakthrough on Therapeutic Approach for Rare Ovarian Cancer

July 27, 2017

(July 27, 2017) Earlier this week, in Nature Cell Biology, researchers at The Wistar Institute published their findings about a few strategies to treat clear cell carcinoma. Clear cell is a rare form of ovarian cancer that does not usually respond well to platinum-based chemotherapy, which leaves patients with few options. In most cases of … Continued

Leading ovarian cancer organization announces 2017 honorees

Leading ovarian cancer organization announces 2017 honorees

July 26, 2017

Largest private funder of ovarian cancer research recognizes top researchers and community leaders NEW YORK — Today, Ovarian Cancer Research Alliance (OCRFA), the nation’s leading ovarian cancer research, advocacy and patient support organization, announces this year’s winners of its research and survivor awards at its annual conference. OCRFA honors two outstanding researchers for their cutting-edge … Continued

USPSTF Does Not Recommend Ovarian Cancer Screening for Gene...

USPSTF Does Not Recommend Ovarian Cancer Screening for General Population

July 19, 2017

(July 19, 2017) The United States Preventative Services Task Force (USPSTF) has once again recommended against screening for ovarian cancer in asymptomatic, average risk women. The draft statement, which was published on July 18th, does not apply to women who are positive for BRCA1 and BRCA2 genetic mutations, who have a higher risk of developing … Continued

Clinical Trial Shows Rucaparib Significantly Improved Progr...

Clinical Trial Shows Rucaparib Significantly Improved Progression-Free Survival in Ovarian Cancer Patients

July 6, 2017

(July 6, 2017) Clovis Oncology, Inc. recently announced topline data from the confirmatory phase 3 ARIEL3 trial of the drug rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied. Read the press release from Clovis Oncology.

Age-Specific Risk in Women with BRCA1 and BRCA2 Mutations

Age-Specific Risk in Women with BRCA1 and BRCA2 Mutations

June 30, 2017

(June 30, 2017) Ten thousand women, most of whom are BRCA1 or BRCA2 positive, were analyzed by the University of Cambridge in order to find age specific risk for breast and ovarian cancers. The goal of the study, which was published in the Journal of the American Medical Association (JAMA), was to better enable clinicians … Continued

Study Focused on Neuropathy in Female Cancer Survivors

Study Focused on Neuropathy in Female Cancer Survivors

June 23, 2017

(June 23, 2017) A clinical trial published in the Journal of Clinical Oncology focused on a largely understudied area of cancer survivorship: chemotherapy-induced peripheral neuropathy (CIPN) in women. Forty seven percent of the 512 women in the trial reported CIPN an average of 6 years after their treatment ended. Symptoms of CIPN reported during the … Continued

An Analysis on the Quality of Life in Long Term Survivors o...

An Analysis on the Quality of Life in Long Term Survivors of Advanced Stage Ovarian Cancer

June 1, 2017

(June 1, 2017) A study, published last month in Gynecologic Oncology, focused on an area of ovarian cancer that is rarely talked about: the quality of life (QOL) for long term survivors of advanced stage ovarian cancer. Woman surviving 8.5 years or longer, who had anywhere from 0 recurrences to multiple recurrences, were given surveys … Continued

The Risk of Blood Clots and Ovarian Cancer

The Risk of Blood Clots and Ovarian Cancer

May 25, 2017

(May 25, 2017) A retrospective study, published earlier this month in Obstetrics & Gynecology, looked at when women with ovarian cancer developed blood clots. One in four women diagnosed with ovarian cancer develop a blood clot, but more specifically, over eleven percent of those who developed a blood clot did so during neoadjuvant chemotherapy. Women … Continued

The Positive Impact of Cognitive Behavior Therapy on Fear o...

The Positive Impact of Cognitive Behavior Therapy on Fear of Cancer Recurrence

May 22, 2017

(May 22, 2017) A recent study from the Netherlands found that a combination of cognitive behavior therapies had a positive effect on FCR, or Fear of Cancer Recurrence. Eighty-eight cancer survivors, including breast, prostate, and colorectal cancers, were divided into either a control group, which received usual care, or the therapy group. The participants that received … Continued

OCRFA Funded Study Determines the Importance of Tumor Antigen

OCRFA Funded Study Determines the Importance of Tumor Antigen

May 2, 2017

(May 2, 2017) A study, published in Gynecologic Oncology, revealed the importance of tumor antigen NY-ESO-1 for ovarian cancer patients. This tumor antigen, although not normally found in healthy cells, is very prevalent in tumors such as epithelial ovarian cancers. Over the course of the 14 year study, Roswell Park tested 1,000 ovarian cancer patients … Continued

Cediranib and its Effect on Quality of Life

Cediranib and its Effect on Quality of Life

April 26, 2017

(April 26, 2017) A study recently published in Cancer evaluates the effect that cediranib, a drugs that stops the growth of new blood vessels, has on a patient’s quality of life (QOL) when used as maintenance therapy. Previous studies have shown that, for patients with relapsed epithelial ovarian cancer, cediranib used as maintenance therapy can … Continued